EXPRESSION OF OSTEOPONTIN IN ORAL SQUAMOUS CELL CARCINOMA – AN IMMUNOHISTOCHEMICAL STUDY
Article Sidebar
Main Article Content
Abstract
Objectives: To analyze the expression of Osteopontin (OPN) is well differentiated, moderately differentiated, and poorly differentiated oral squamous cell carcinoma (OSCC).
Methodology: This study was conducted at the Department of Pathology, Peshawar Medical College, over a period of 12 months. A total of 50 formalin-fixed paraffin-embedded (FFPE) blocks (n=50) of confirmed cases with varying grades of OSCC were included in the study. Immunostaining was evaluated for intensity and percentage of positive cells and Immunoreactivity of OPN was assessed by the Immunoreactivity scoring system (IRS) method.
Results: The age of the patients was 58.44 ± 13.01 years ranging from 30 to 82 years on average. Maximum number of cases belonged to the age group 51 to 70 years having 27 (54%) participants. The most common category of OPN expression among well differentiated OSCC was moderate (n=16, 66.7%). For poorly differentiated OSCC the strong staining was found in 6 cases (50%) and was the most common category of OPN expression. In males the pattern of staining for OPN expression was not statistically significant among various grades of OSCC (P=0.455) while among females the results were highly significant (P=0.003). The mean IHC staining score by IRS method for OPN expression was highest among well differentiated (9.20±4.31)
Conclusion: OPN can be used as a diagnostic marker for OSCC. It can also help in assessing the potential aggressive behavior of the tumor pointing at close follow up of such patients for recurrence.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017;70:23- 8. DOI:10.1016/j.oraloncolo¬gy.2017.05.004.
Shahid Mahmood RF, Yousaf A, Ain Ul Quader H, Asif A, Atif M, Waseem F. Cancer Registry and Clinical Data Man¬agement (CRCDM). Shaukat Khanum Memorial Cancer Hospital and Re¬search Center. 2016:4-8.
Sarwar MR, Saqib A. Cancer preva¬lence, incidence and mortality rates in Pakistan in 2012. Cogent Med. 2017;4(1):1288773.
Tiwana MS, Wu J, Hay J, Wong F, Cheung W, Olson RA. 25 year sur¬vival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. Oral Oncol. 2014 ;50(7):651-6. DOI:10.1016/j.oraloncol¬ogy.2014.03.009.
Choi S, Myers JN. Molecular pathogen¬esis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87(1):14-32. DOI:10.1177/1544 05910808700104.
Henry NL, Hayes DF. Cancer biomark¬ers. Mol Oncol. 2012 Apr;6(2):140-6. DOI:10.1016/j.molonc.2012.01.010.
Salem M, Atti SA, Raziky ME, Darweesh SK, Sharkawy ME. Clinical Significance of Plasma Osteopontin Level as a Bio¬marker of Hepatocellular Carcinoma. Gastroenterology Res. 2013;6(5):191- 99. DOI:10.4021/gr499w.
Routray S, Kheur SM, Kheur M. Os¬teopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias. Ann Diagn Pathol. 2013 Oct;17(5):421-4. DOI:10.1016/j.anndi¬agpath.2013.03.005. .
Subramani VN, Narasimhan M, Thi¬yagarajan M, Munuswamy BD, Jaya¬mani L. Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohis¬tochemical Study. J Clin Diagn Res. 2015;9(11):ZC66-9. DOI:10.7860/ JCDR/2015/12777.6836.
Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, et al. Compre¬hensive study on the prognostic role of osteopontin expression in oral squa¬mous cell carcinoma. Oral Oncol. 2009 Sep;45(9):798-802. DOI:10.1016/j. oraloncology.2008.12.006
Jeyasivanesan DL, Mohamed SP, Pan¬diar D, Basheer S. Immunohistochem¬ical analysis of osteopontin expression in oral squamous cell carcinoma. In¬dian J Dent Res. 2019;30(4):539-43. DOI:10.4103/ijdr.IJDR_474_17.
Subraman V, Thiyagarajan M, Malathi N, Rajan ST. OPN -Revisited. J Clin Diagn Res. 2015;9(6):ZE10-3. DOI:10.7860/ JCDR/2015/12872.6111.
Grizzle WE, Myers RB, Manne U, Sri¬vastava S. Immunohistochemical Eval¬uation of Biomarkers in Prostatic and Colorectal Neoplasia: Principles and Guidelines. Tumor marker protocols. 1998:143-60.
Pires FR, Ramos AB, Oliveira JB, Tavares AS, Luz PS, Santos TC. Oral squamous cell carcinoma: clinicopathological fea¬tures from 346 cases from a single oral pathology service during an 8-year pe¬riod. J Appl Oral Sci. 2013;21(5):460-7. DOI:10.1590/1679-775720130317.
Naseer R, Naz I, Mahmood MK. Fre¬quency of Delayed Diagnosis of Oral Squamous Cell Carcinoma in Pa¬kistan. Asian Pac J Cancer Prev. 2016;17(11):5037-40. DOI:10.22034/ APJCP.2016.17.11.5037.
Alamgir M, Jamal Q, Jafarey N, Mirza T. Clinicopathological parameters of 50 oral squamous cell carcinoma cases in Karachi. Pak J Med Dent. 2013;2(2):3- 8.
Ayaz B, Saleem K, Azim W, Shaikh A. A clinico-pathological study of oral can¬cers. Biomedica. 2011;27(1). 29-32.
Isaac JS, Qureshi NR, Isaac U. Report on oral cancers patients at atomic en¬ergy medical center, Jamshoro during the year 2002: A Pilot Study. J Pak Dent Assoc. 2003;12(3):176-8.
Ali M, Bhatti A, Tariq M, Khan S, Sarwar G, Waheed K, et al. An epidemiological study of 202 cases of oral cavity cancer (OCC) in Pakistani subjects. Biomedica, 1998;14:27-31.
Sahaf R, Naseem N, Rehman A, Anjum R, Nagi AH. A Study of 89 Cases of Oral Squamous Cell Carcinoma Presenting at Teaching Hospitals of Lahore, Pakistan. J Pak Dent Assoc. 2017; 26(1):27-31.
Rummana A, Zeeshan A, Aneela A, Ammara A, Faisal A, Tahmasub FT. Examine the prevalence of oral squa¬mous cell carcinoma also determine the risk factors and causes of improp¬er diagnosis. Pak J Med Health Sci. 2019;13(13):831-7.
Kashif M, Minhas S, Nazi A. A clini¬co-morphological study of oral squa¬mous cell carcinoma in Pakistan. Int J Curr Res. 2015;7:17401-5.
Avirovic M, Matusan-Ilijas K, Damante G, Fabrro D, Cerovic R, Juretic M, et al. Osteopontin expression is an inde¬pendent factor for poor survival in oral squamous cell carcinoma: a comput¬er-assisted analysis on TMA sections. J Oral Pathol Med. 2013;42(8):620-6.
Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, et al. Osteopontin as biomarker in ear¬ly invasion by squamous cell carci¬noma in tongue. J Oral Pathol Med. 2007;36(1):30-4. DOI:10.1111/ j.1600-0714.2006.00493.x.
Aravind T, Janardhanan M, Rakesh S, Savithri V, Unnikrishnan UG. Immuno¬localization of osteopontin in dyspla¬sias and squamous cell carcinomas arising from oral epithelium. J Oral Maxillofac Pathol. 2017;21(1):18-23. DOI:10.4103/0973-029X.203764.
Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med. 1999;28(3):97-101. DOI:10.1111/j.1600-0714.1999. tb02004.x.